Vivotif

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Typhoid Fever

Conditions

Typhoid Fever

Trial Timeline

Aug 26, 2015 → Feb 21, 2017

NCT ID

NCT02391909

About Vivotif

Vivotif is a pre-clinical stage product being developed by Bavarian Nordic for Typhoid Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT02391909. Target conditions include Typhoid Fever.

What happened to similar drugs?

0 of 1 similar drugs in Typhoid Fever were approved

Approved (0) Terminated (0) Active (1)

🔄Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCVZydus LifesciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02391909	Pre-clinical	Completed	Aug 26, 2015	Feb 21, 2017	Typhoid Fever

Competing Products

7 competing products in Typhoid Fever

See all competitors

Product	Company	Stage	Hype Score
Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV	Zydus Lifesciences	Phase 3	47
Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine	Novartis	Phase 2	35
NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine	Novartis	Phase 2	35
Typherix + NVGH Vi-CRM197	Novartis	Phase 1	29
NVGH Vi-CRM197	Novartis	Phase 2	35
Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine	Novartis	Phase 2	35
Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4)	Emergent BioSolutions	Phase 2	25